United Therapeutics Corporation

Biotechnology company announces adoption of 10b5-1 trading plans

Published in Cardiovascular Business Week, April 13th, 2004

United Therapeutics Corporation (UTHR) announced that its Chief Financial Officer Fred Hadeed and its General Counsel Paul Mahon have each adopted pre-arranged stock trading plans to sell a portion of their company stock over 3 years as part of their individual long-term strategy for asset diversification and liquidity.

The stock trading plans were adopted in accordance with guidelines specified under Securities and Exchange Commission Rule 10b5-1 and United Therapeutics' Securities Trades by Company Personnel Policy

In addition, Bina Aspen Rothblatt, the spouse of chief executive officer Martine Rothblatt, has also adopted a 3-year Rule 10b5-1 stock...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2004-04-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry